


Amendments to the Claims


The listing of claims will replace all prior versions and listing of claims in the application:


Listing of Claims:

5 Claims 1-30: Cancelled.

Claim 31 (currently amended): A compound of the formula:







or a pharmaceutically acceptable salt or solvate thereof.

Claim 32 (currently amended): A method of inhibiting one or more cyclin dependent kinases, comprising administering a therapeutically effective amount of at least one compound of claim 4 31 to a patient in need of such inhibition.

Claim 33 (currently amended): A method of treating one or more diseases associated with a cyclin-dependent kinase, comprising administering a therapeutically effective amount of at least one compound of claim 4 31 to a patient in need of such treatment.

Claim 34 (currently amended): The method of claim 33, wherein said cyclin dependent kinase is CDK2.

Claim 35 (currently amended): The method of claim 33, wherein said cyclin dependent kinase is mitogen activated protein kinase (MAPK/ERK).

Claim 36 (currently amended): The method of claim 33, wherein said cyclin dependent kinase is glycogen synthase kinase 3 (GSK3beta).

Claim 37 (original): The method of claim 33, wherein said disease is selected from the group consisting of:

cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia,
5 B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

10 astrocytoma, neuroblastoma, glioma and schwannomas;

melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 38 (currently amended): A method of treating one or more diseases
15 associated with cyclin dependent kinase, comprising administering to a mammal in need of such treatment

an amount of a first compound, which is a compound of claim 1, or a pharmaceutically acceptable salt ~~or solvate~~ thereof;
and

20 an amount of at least one second compound, said second compound being an anti-cancer agent;

wherein the amounts of the first compound and said second compound result in a therapeutic effect.

Claim 39 (original): The method of claim 38, further comprising radiation
25 therapy.


Claim 40 (original): The method of claim 38, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate,
30 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine,

- Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin,
- 5 Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,
- 10 Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine..
- 15 Claim 41 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 4 31 in combination with at least one pharmaceutically acceptable carrier.
- Claim 42 (original): The pharmaceutical composition of claim 39, additionally comprising one or more anti-cancer agents selected from the group consisting
- 20 of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan,
- 25 gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine,
- 30 Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone,

Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, 5 Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 43 (currently amended): A compound of claim 4 31 in purified form.


Claim 44 (currently amended): A compound of the formula:



10


or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 45 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

15 Claim 46 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 47 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt or solvate thereof.

Claim 48 (currently amended): A compound of the formula:




5 or a pharmaceutically acceptable salt or solvate thereof.

Claim 49 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt or solvate thereof.

Claim 50 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt or solvate thereof.

Claim 51 (currently amended): A compound of the formula:




or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 52 (currently amended): A compound of the formula:




5 or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 53 (currently amended): A compound of the formula:



or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 54 (new claim): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 55 (new claim): A method of inhibiting one or more cyclin dependent kinases, comprising administering a therapeutically effective amount of at least one compound of any of claims 44-54 to a patient.

5 Claim 56 (new claim): A method of treating one or more diseases associated with a kinase, comprising administering a therapeutically effective amount of at least one compound of any of claims 44-54 to a patient.

Claim 57 (new claim) The method of claim 56, wherein said disease is selected from the group consisting of:

10 cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

15 acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

20 melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 58 (new claim): A method of treating one or more diseases associated with cyclin dependent kinase, comprising administering to a mammal in need of such treatment

25 an amount of a first compound, which is a compound of claim 44-54, or a pharmaceutically acceptable salt thereof;
and

an amount of temozolomide;

30 wherein the amounts of the first compound and said temozolomide result in a therapeutic effect.

Claim 59 (original): The method of claim 58, further comprising radiation therapy.

Claim 60 (new claim): A pharmaceutical composition comprising (i) a therapeutically effective amount of a compound of claim 44-54 or a pharmaceutically acceptable salt thereof, and (ii) temozolomide.

5 Claim 61 (new claim): A method of inhibiting one or more kinases, comprising administering the pharmaceutical composition of claim 60.

Claim 62 (new claim): The method of claim 61 wherein said kinase is a cyclin dependent kinase.

10 Claim 63 (new claim): A method of treating one or more diseases associated with a kinase, comprising administering the pharmaceutical composition of claim 60.

Claim 64 (new claim): A method of treating a cancer, comprising administering the pharmaceutical composition of claim 60.

15 Claim 65 (new claim): A method of treating a cancer, comprising administering a therapeutically effective amount of at least one compound of claim 31.

Claim 66 (new claim): The method of claim 65, wherein said cancer is selected from the group consisting of:

20 cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T- cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

25 acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;

fibrosarcoma, rhabdomyosarcoma;

astrocytoma, neuroblastoma, glioma and schwannomas;

30 melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Claim 67 (new claim): A method of treating a cancer, comprising administering to a mammal in need of such treatment

an amount of a first compound, which is a compound of claim 31, or a pharmaceutically acceptable salt thereof;

and

an amount of at least one second compound, said second compound being an anti-cancer agent;

wherein the amounts of the first compound and said second compound result in a therapeutic effect.

Claim 68 (new claim): The method of claim 67, further comprising radiation therapy.

Claim 69 (new claim): The method of claim 67, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methotrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chloromethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATINTM, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Claim 70 (new claim): A method of treating a cancer, comprising administering (i) a therapeutically effective amount of at least one compound of claim 31, and (ii) temozolomide.